BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ibrahim SM, Ringel J, Schmidt C, Ringel B, Müller P, Koczan D, Thiesen HJ, Löhr M. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas. 2001;23:72-79. [PMID: 11451151 DOI: 10.1097/00006676-200107000-00011] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Schneider G, Siveke JT, Eckel F, Schmid RM. Pancreatic cancer: basic and clinical aspects. Gastroenterology. 2005;128:1606-1625. [PMID: 15887154 DOI: 10.1053/j.gastro.2005.04.001] [Cited by in Crossref: 210] [Cited by in F6Publishing: 204] [Article Influence: 12.4] [Reference Citation Analysis]
2 Beyer K, Normann L, Sendler M, Käding A, Heidecke CD, Partecke LI, von Bernstorff W. TRAIL Promotes Tumor Growth in a Syngeneic Murine Orthotopic Pancreatic Cancer Model and Affects the Host Immune Response. Pancreas 2016;45:401-8. [PMID: 26390425 DOI: 10.1097/MPA.0000000000000469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
3 Maguire CA, Bovenberg MS, Crommentuijn MH, Niers JM, Kerami M, Teng J, Sena-Esteves M, Badr CE, Tannous BA. Triple bioluminescence imaging for in vivo monitoring of cellular processes. Mol Ther Nucleic Acids 2013;2:e99. [PMID: 23778500 DOI: 10.1038/mtna.2013.25] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
4 Beyer K, Partecke LI, Roetz F, Fluhr H, Weiss FU, Heidecke CD, von Bernstorff W. LPS promotes resistance to TRAIL-induced apoptosis in pancreatic cancer. Infect Agent Cancer. 2017;12:30. [PMID: 28572836 DOI: 10.1186/s13027-017-0139-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
5 Christgen M, Schniewind B, Jueschke A, Ungefroren H, Kalthoff H. Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells. Cancer Letters 2005;227:193-200. [DOI: 10.1016/j.canlet.2005.01.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
6 Samel S, Keese M, Lux A, Jesnowski R, Prosst R, Saller R, Hafner M, Sturm J, Post S, Löhr M. Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide. Cancer Gene Ther. 2006;13:65-73. [PMID: 16096652 DOI: 10.1038/sj.cgt.7700849] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
7 Kang BH, Jensen KJ, Hatch JA, Janes KA. Simultaneous profiling of 194 distinct receptor transcripts in human cells. Sci Signal 2013;6:rs13. [PMID: 23921087 DOI: 10.1126/scisignal.2003624] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
8 Huang M, Zhu H, Yi C, Yan J, Wei L, Yang X, Chen S, Huang Y. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer. Cancer Chemother Pharmacol 2018;82:829-38. [PMID: 30167846 DOI: 10.1007/s00280-018-3658-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Vogler M, Dürr K, Jovanovic M, Debatin K, Fulda S. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007;26:248-57. [DOI: 10.1038/sj.onc.1209776] [Cited by in Crossref: 83] [Cited by in F6Publishing: 74] [Article Influence: 5.2] [Reference Citation Analysis]
10 Wachsmann MB, Pop LM, Vitetta ES. Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med. 2012;60:643-663. [PMID: 22406516 DOI: 10.231/jim.0b013e31824a4d79] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Du B, Zhao Z, Sun H, Ma S, Jin J, Zhang Z. Effects of 2-methoxyestradiol on proliferation, apoptosis and gene expression of cyclin B1 and c-Myc in esophageal carcinoma EC9706 cells: EFFECTS OF 2-ME ON CYCLIN B1 AND C-MYC. Cell Biochem Funct 2012;30:158-65. [DOI: 10.1002/cbf.1830] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
12 Shen HW, Gao SL, Wu YL, Peng SY. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol 2005; 11(38): 5926-5930 [PMID: 16273601 DOI: 10.3748/wjg.v11.i38.5926] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
13 Kim H, Morgan DE, Buchsbaum DJ, Zeng H, Grizzle WE, Warram JM, Stockard CR, McNally LR, Long JW, Sellers JC, Forero A, Zinn KR. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res 2008;68:8369-76. [PMID: 18922909 DOI: 10.1158/0008-5472.CAN-08-1771] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
14 Chen G, Rong M, Luo D. TNFRSF6B neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell. Pathol Res Pract 2010;206:631-41. [PMID: 20591579 DOI: 10.1016/j.prp.2010.05.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
15 Han Z, Lee S, Je S, Eom C, Choi HJ, Song JJ, Kim J. Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells. Apoptosis 2016;21:351-64. [DOI: 10.1007/s10495-015-1208-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
16 Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C, Zangemeister-Wittke U, Stahel R. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 2003;10:356-364. [PMID: 12700635 DOI: 10.1038/sj.cdd.4401157] [Cited by in Crossref: 182] [Cited by in F6Publishing: 156] [Article Influence: 9.6] [Reference Citation Analysis]
17 Wolf S, Mertens D, Pscherer A, Schroeter P, Winkler D, Gröne HJ, Hofele C, Hemminki K, Kumar R, Steineck G, Döhner H, Stilgenbauer S, Lichter P. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer 2006;118:1831-5. [PMID: 16217763 DOI: 10.1002/ijc.21502] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
18 Doi T, Murakami H, Ohtsu A, Fuse N, Yoshino T, Yamamoto N, Boku N, Onozawa Y, Hsu CP, Gorski KS, Friberg G, Kawaguchi T, Sasaki T. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;68:733-41. [PMID: 21161528 DOI: 10.1007/s00280-010-1544-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
19 Katz MH, Spivack DE, Takimoto S, Fang B, Burton DW, Moossa AR, Hoffman RM, Bouvet M. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Ann Surg Oncol. 2003;10:762-772. [PMID: 12900367 DOI: 10.1245/aso.2003.01.021] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
20 Collignon A, Silvy F, Robert S, Trad M, Germain S, Nigri J, André F, Rigot V, Tomasini R, Bonnotte B, Lombardo D, Mas E, Beraud E. Dendritic cell-based vaccination: powerful resources of immature dendritic cells against pancreatic adenocarcinoma. Oncoimmunology 2018;7:e1504727. [PMID: 30524902 DOI: 10.1080/2162402X.2018.1504727] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Guillermet J, Saint-Laurent N, Rochaix P, Cuvillier O, Levade T, Schally AV, Pradayrol L, Buscail L, Susini C, Bousquet C. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci U S A 2003;100:155-60. [PMID: 12490654 DOI: 10.1073/pnas.0136771100] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 4.3] [Reference Citation Analysis]
22 Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J, Repasky EA. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 2005;3:22. [PMID: 15943879 DOI: 10.1186/1479-5876-3-22] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 4.5] [Reference Citation Analysis]
23 Younes M, Georgakis GV, Rahmani M, Beer D, Younes A. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma. European Journal of Cancer 2006;42:542-7. [DOI: 10.1016/j.ejca.2005.11.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
24 Rychahou PG, Murillo CA, Evers BM. Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL). Surgery. 2005;138:391-397. [PMID: 16153452 DOI: 10.1016/j.surg.2005.05.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
25 Saidi RF, Williams F, Ng J, Danquah G, Mittal VK, Remine SG, Jacobs MJ. Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines. The American Journal of Surgery 2006;191:358-63. [DOI: 10.1016/j.amjsurg.2005.10.037] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
26 Retzer-Lidl M, Schmid RM, Schneider G. Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. Int J Cancer 2007;121:66-75. [PMID: 17304504 DOI: 10.1002/ijc.22619] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
27 Wang P, Zhang J, Bellail A, Jiang W, Hugh J, Kneteman NM, Hao C. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal. 2007;19:2237-2246. [PMID: 17693058 DOI: 10.1016/j.cellsig.2007.06.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
28 Hammer K, Kazcorowski A, Liu L, Behr M, Schemmer P, Herr I, Nettelbeck DM. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells. Int J Cancer. 2015;137:978-990. [PMID: 25604186 DOI: 10.1002/ijc.29442] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
29 Thaver V, Lottering ML, van Papendorp D, Joubert A. In vitro effects of 2-methoxyestradiol on cell numbers, morphology, cell cycle progression, and apoptosis induction in oesophageal carcinoma cells. Cell Biochem Funct 2009;27:205-10. [PMID: 19343733 DOI: 10.1002/cbf.1557] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
30 Chen LH, Liu XS, Wang WY, Han WN, Pan BR, Jin BQ. Localization of TRAIL/TRAILR in fetal pancreas. World J Gastroenterol 2003; 9(2): 334-337 [PMID: 12532461 DOI: 10.3748/wjg.v9.i2.334] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
31 Tolcher AW. Regulators of apoptosis as anticancer targets. Hematol Oncol Clin North Am 2002;16:1255-67. [PMID: 12512391 DOI: 10.1016/s0889-8588(02)00046-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Gukovskaya AS, Pandol SJ. Cell death pathways in pancreatitis and pancreatic cancer. Pancreatology. 2004;4:567-586. [PMID: 15550766 DOI: 10.1159/000082182] [Cited by in Crossref: 105] [Cited by in F6Publishing: 105] [Article Influence: 5.8] [Reference Citation Analysis]
33 Lin WW, Hsieh SL. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol. 2011;81:838-847. [PMID: 21295012 DOI: 10.1016/j.bcp.2011.01.011] [Cited by in Crossref: 108] [Cited by in F6Publishing: 102] [Article Influence: 9.8] [Reference Citation Analysis]
34 Chen H, Chen J, Shun C, Tsai Y, Ho H. Decoy receptor 3 expression during the menstrual cycle and pregnancy, and regulation by sex steroids in endometrial cells in vitro. Human Reproduction 2009;24:1350-8. [DOI: 10.1093/humrep/dep028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
35 Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H, Ungefroren H. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer. 2004;109:182-188. [PMID: 14750167 DOI: 10.1002/ijc.11679] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 4.4] [Reference Citation Analysis]
36 Sinha K, Chowdhury S, Banerjee S, Mandal B, Mandal M, Majhi S, Brahmachari G, Ghosh J, Sil PC. Lupeol alters viability of SK-RC-45 (Renal cell carcinoma cell line) by modulating its mitochondrial dynamics. Heliyon 2019;5:e02107. [PMID: 31417967 DOI: 10.1016/j.heliyon.2019.e02107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
37 He C, Lao WF, Hu XT, Xu XM, Xu J, Fang BL. Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects. World J Gastroenterol 2004; 10(5): 654-659 [PMID: 14991932 DOI: 10.3748/wjg.v10.i5.654] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
38 DeRosier LC, Huang ZQ, Sellers JC, Buchsbaum DJ, Vickers SM. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo. J Gastrointest Surg 2006;10:1291-300; discussion 1300. [PMID: 17114015 DOI: 10.1016/j.gassur.2006.08.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
39 Wang W, Zhang M, Sun W, Yang S, Su Y, Zhang H, Liu C, Li X, Lin L, Kim S. Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer. PLoS One. 2013;8:e74272. [PMID: 24204567 DOI: 10.1371/journal.pone.0074272] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
40 Kang D, Choi HJ, Kang S, Kim SY, Hwang YS, Je S, Han Z, Kim JH, Song JJ. Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells. Cell Signal 2015;27:807-17. [PMID: 25615626 DOI: 10.1016/j.cellsig.2015.01.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
41 Yang LQ, Fang DC, Wang RQ, Yang SM. Effect of NF-κB, survivin, Bcl-2 and Caspase3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. World J Gastroenterol 2004; 10(1): 22-25 [PMID: 14695762 DOI: 10.3748/wjg.v10.i1.22] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 44] [Article Influence: 2.3] [Reference Citation Analysis]
42 Humphreys RC, Halpern W. Trail Receptors: Targets for Cancer Therapy. Programmed Cell Death in Cancer Progression and Therapy. Dordrecht: Springer Netherlands; 2008. pp. 127-58. [DOI: 10.1007/978-1-4020-6554-5_7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
43 Crommentuijn MH, Maguire CA, Niers JM, Vandertop WP, Badr CE, Würdinger T, Tannous BA. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma. Mol Oncol 2016;10:625-34. [PMID: 26708508 DOI: 10.1016/j.molonc.2015.11.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
44 Röder C, Trauzold A, Kalthoff H. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. European Journal of Cell Biology 2011;90:450-5. [DOI: 10.1016/j.ejcb.2010.10.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
45 Wu YF, Cao MF, Gao YP, Chen F, Wang T, Zumbika EP, Qian KX. Down-modulation of heat shock protein 70 and up-modulation of Caspase-3 during schisandrin B-induced apoptosis in human hepatoma SMMC-7721 cells. World J Gastroenterol 2004; 10(20): 2944-2948 [PMID: 15378770 DOI: 10.3748/wjg.v10.i20.2944] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
46 Yoo S, Jang J, Kim S, Cho H, Lee M. Expression of DcR3 and Its Effects in Kaposi’s Sarcoma-Associated Herpesvirus-Infected Human Endothelial Cells. Intervirology 2012;55:45-52. [DOI: 10.1159/000323522] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
47 Murtaza I, Saleem M, Adhami VM, Hafeez BB, Mukhtar H. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res. 2009;69:1156-1165. [PMID: 19176377 DOI: 10.1158/0008-5472.CAN-08-2917] [Cited by in Crossref: 66] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
48 Feng N, Jin H, Wang M, Du C, Wright JA, Young AH. Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts. Cancer Chemother Pharmacol 2003;51:247-55. [PMID: 12655444 DOI: 10.1007/s00280-002-0559-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
49 Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS, Sanlioglu S. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. Pancreas 2009;38:154-60. [PMID: 18981952 DOI: 10.1097/MPA.0b013e31818db9e3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
50 Yang F, Shi P, Xi X, Yi S, Li H, Sun Q, Sun M. Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC). Med Oncol 2006;23:191-204. [PMID: 16720919 DOI: 10.1385/MO:23:2:191] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
51 Sahu RP, Batra S, Kandala PK, Brown TL, Srivastava SK. The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines. Cancer Chemother Pharmacol 2011;67:481-7. [PMID: 20848283 DOI: 10.1007/s00280-010-1463-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
52 Wachsmann MB, Pop LM, Vitetta ES. Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med 2012;60:643-63. [PMID: 22406516 DOI: 10.2310/JIM.0b013e31824a4d79] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
53 Wu X, Zhang ZX, Chen XY, Xu YL, Yin N, Yang J, Zhu DM, Li DC, Zhou J. A Panel of Three Biomarkers Identified by iTRAQ for the Early Diagnosis of Pancreatic Cancer. Proteomics Clin Appl 2019;13:e1800195. [PMID: 31025496 DOI: 10.1002/prca.201800195] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
54 Tekmen I, Ozyurt D, Pekçetin C, Buldan Z. The effect of TRAIL molecule on cell viability in in vitro beta cell culture. Acta Diabetol 2007;44:60-4. [PMID: 17530468 DOI: 10.1007/s00592-007-0243-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
55 Connor JP, Felder M. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol Oncol. 2008;111:330-335. [PMID: 18723214 DOI: 10.1016/j.ygyno.2008.07.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
56 Qanungo S, Basu A, Das M, Haldar S. 2-Methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells. Oncogene. 2002;21:4149-4157. [PMID: 12037671 DOI: 10.1038/sj.onc.1205508] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
57 Moniri MR, Sun XY, Rayat J, Dai D, Ao Z, He Z, Verchere CB, Dai LJ, Warnock GL. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther. 2012;19:652-658. [PMID: 22767216 DOI: 10.1038/cgt.2012.46] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
58 Huang L, Xu J, Li K, Zheng MH, Kumta S. Thapsigargin potentiates TRAIL-induced apoptosis in giant cell tumor of bone. Bone 2004;34:971-81. [DOI: 10.1016/j.bone.2004.02.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
59 Kanzaki H, Ohtaki A, Merchant FK, Greene MI, Murali R. Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells. Exp Mol Pathol. 2013;94:372-379. [PMID: 23219833 DOI: 10.1016/j.yexmp.2012.11.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]